LignaMed
2013
FOUNDED
PRIVATE
STATUS
Accelerator/Inc
LATEST DEAL TYPE
3
INVESTORS
Description
Developer of molecule therapy for the treatment for cancer. The company develops therapeutics from flaxseed derivatives to amplify effects of chemotherapy and radiation treatment on cancer cells.
Website
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Other Healthcare
Primary Office
- Philadelphia, PA
- United States
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore LignaMed’s full profile, request a free trial.
LignaMed Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Accelerator/Incubator | 10-Mar-2015 | Completed | Startup | |||
| 2. Accelerator/Incubator | 04-Mar-2015 | Completed | Startup | |||
| 1. Grant | 18-Jan-2014 | $825K | Completed | Startup |
LignaMed Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| UPstart | Accelerator/Incubator | 000 0000 | 000000 0 | |||
| Science Center | Accelerator/Incubator | 000 0000 | 000000 0 | |||
| National Institutes of Health | Government | 000 0000 | 000000 0 |
LignaMed Executive Team (3)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Thais Sielecki | Chief Scientific Officer | ||
| Melpo Christofidou Solomidou Ph.D | Founder & Chair of Scientific Advisory Board | ||
| Jim Harris | Chief Executive Officer |